At the IGTP TODAY

News

- Innovation, Research

Biointaxis launches a 0.88M euro crowdfunding campaign to finance a curative therapy for Friedreich's Ataxia

Biointaxis is a spin-off of the IGTP led by Dr. Antoni Matilla-Dueñas. To date, the research has been financed with the support of patient associations, the founders themselves, La Caixa Foundation, the CDTI and the Ministry of Science and Innovation. The project, that received the European seal of excellence in 2020, is in the final phase of gene therapy after years of research progress and it is the only candidate with potential to cure the disease at the moment. This round aims to overcome  the critical inflexion point - the demonstration of the biodistribution and safety of the therapy in non-human primates. The value of the company will increase considerably when this data is available in less than 1 year; the financing campaign is being carried out through the equity crowdfunding platform of Capital Cell.

- Innovation, Research

A new IGTP spin-off to develop a medical device for improving the diagnostics and prognostics of acute ischaemic stroke

Researchers from the Germans Trias i Pujol Research Institute (IGTP) together with doctors from the hospital have developed a medical device to improve the diagnostics and prognostics of acute ischaemic stroke. The objective of the technology is to optimize the current clinical algorithm for this type of ictus so that medical staff can take the correct decisions for each patient, before and after admission to hospital. To develop the medical device the spin-off company Time is Brain, led by Dr Alicia Martínez-Piñeiro has been created by the IGTP.

- Innovation, Research

The IGTP participates in an international project to validate serological tests for COVID-19

The Innovation in Respiratory Infection and Tuberculosis Diagnosis research group led by Dr José Dominguez and Dr Cristina Prat Aymerich have started a collaboration with the team led by Dr Lluis Cuevas at the Liverpool School of Tropical Medicine to develop and validate new serological techniques for diagnosing COVID-19. The project is financed by the Wellcome Trust (UK).

The IGTP coordinates a clinical trial to reduce the number of infections by SARS-CoV-2

The clinical trial will test whether the food supplement Manremyc® protects against infection with SARS-CoV-2 and starts this May. The Pharmaceutical company Reig Jofre is the sponsor of the trial. It is coordinated from the Germans Trias i Pujol Research Institute together with the IDIAP Jordi Gol Foundation. The trial will last three months and results are expected in October 2020.

100 RESPIRA ventilators from GAPInnova delivered to the SEM to continue clinical trials with COVID-19 patients in other hospitals

The emergency ventilator RESPIRA, developed by GPAINNOVA, with the support of the Hospital Clínic, Barcelona, the Germans Trias i Pujol Research Institute and the University of Barcelona have passed the first stage of the clinical trial with the first two patients affected by COVID-19 successfully. With the first phase complete, the study can be expanded to other hospitals in the region. Thanks to the support received from the public, companies and administrations today the first 100 emergency ventilators c have been delivered to the SEM for distribution.

The autonomous ventilation device (DAR) developed by the Hospital Clínic Barcelona, Germans Trias i Pujol, the University of Barcelona and GASN2 is authorized by the AEMPS to start clinical trials

The Spanish Agency of Medicines and Medical Devices (AEMPS) has today given the green light to test the device developed by the company GasN2 with the support of professionals from the Hospital Clínic Barcelona, the Germans Trias i Pujol Research Institute (IGTP) and the University of Barcelona (UB). The prototype uses a system of electro pneumatic valves to supply and control the volume of oxygen necessary for each patient. Support from civil society, companies and administrations has been key to the development of the design and industrial scaling up of the model to contribute to the provision of the ventilators needed by the health system.